Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Online

Proarrhythmia

Speakers

Norman  Stockbridge, MD, PhD

Norman Stockbridge, MD, PhD

Director, Division of Cardiology and Nephrology, OND, CDER, FDA, United States

Norman Stockbridge, MD, PhD has been in FDA/CDER's Division of Cardiovascular and Renal Products since 1991 and has been its Director since 2004.

Blake D. Anson, PhD

Blake D. Anson, PhD

Product Manager, iCell Cardiomyocytes, Cellular Dynamics International, Inc, United States

Gary  Gintant, PhD

Gary Gintant, PhD

Research Fellow, AbbVie Inc., United States

Gary Gintant is a Research Fellow in the Dept. of Integrative Pharmacology, Global Pharmaceutical R&D, AbbVie. He is also a member of the CiPA Steering Committee and Co-Chair of the HESI Stem Celll-Cardiomyocyte Working Group.

Börje C. Darpö, MD, PhD

Börje C. Darpö, MD, PhD

Chief Scientific Officer, Cardiac Safety, Clario, Sweden

Borje Darpo received is a board certified cardiologist since 1989. He specialized in clinical electrophysiology and presented his thesis on the clinical development of an antiarrhythmic drug in 1995. In 1998 he was appointed Fellow of the European Heart Association and in 2000 Associate Professor in Cardiology at the Karolinska Institute in Stockholm. In 1998 he joined Pharmacia and has held positions as Clinical Program Leader in Cardiovascular, Regional Head of EU for Clinical Pharmacology and Senior Director in Pfizer’s Clinical Technologies group in Sandwich, UK. Between April 2004 and March 2006, Dr Darpo held the position as Chief Medical Officer of Daiichi Medical Research in UK and USA.

David  Strauss, MD, PhD

David Strauss, MD, PhD

Director, Division of Applied Regulatory Science, OCP, OTS, CDER, FDA, United States

Dr. Strauss is a physician-scientist with experience in experimental and clinical research along with regulatory evaluation for drugs and medical devices. He currently serves as Director of FDA's Division of Applied Regulatory Science, which seeks to move new science into the FDA review process, closing the gap between scientific innovation and medical product review. With ICH, he is rapporteur of the E14/S7B working group to develop Q&As on the Clinical and Non-Clinical Evaluation of QT/QTc Prolongation and Proarrhythmic Potential. He has published over 150 peer-reviewed journal articles or book chapters. He received both a B.A. in chemistry and M.D. from Duke Univ, and a Ph.D. in clinical physiology from Lund University.

Have an account?

Ways to register

Series Discount Available*

Save when you purchase two or more webinars in this series.
Buy two, save 10%
Buy three, save 15%

*Includes archived webinars in this series. Order must be placed in one transaction for savings to be applied.



Printable Registration Form

  • Individual registration is a license for ONE internet login allowing one viewer.
  • Group site registration is a license for ONE internet login allowing multiple viewers from one location.
  • Group Plus is a license for up to FIVE internet logins allowing one or more viewers at each login location.


Cancellations:  No refunds will be provided in the event of a participant’s cancellation since all costs for this webinar have been prepaid by DIA. DIA reserves the right to modify or cancel programs and/or substitute presenters or panelists. DIA is not responsible for failure to deliver programs due to circumstances beyond its control.

Participants with Disabilities: Reasonable accommodations will be made available to persons with disabilities who attend an educational activity. Contact the DIA office in writing at least 15 days prior to event to indicate your needs.

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.